Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I, Open-label, Single Dose Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics (PK) of Evobrutinib (M2951) Compared to Normal Renal Function in Male and Female Subjects

Trial Profile

Phase I, Open-label, Single Dose Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics (PK) of Evobrutinib (M2951) Compared to Normal Renal Function in Male and Female Subjects

Recruiting
Phase of Trial: Phase I

Latest Information Update: 11 Dec 2018

At a glance

  • Drugs Evobrutinib (Primary)
  • Indications Autoimmune disorders; Encephalomyelitis; Multiple sclerosis; Rheumatoid arthritis; Systemic lupus erythematosus
  • Focus Pharmacokinetics
  • Sponsors Merck KGaA
  • Most Recent Events

    • 27 Nov 2018 Planned End Date changed from 6 Dec 2018 to 27 Feb 2019.
    • 27 Nov 2018 Planned primary completion date changed from 6 Dec 2018 to 27 Feb 2019.
    • 27 Nov 2018 Status changed from completed to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top